Bank of America
NGEN

Bank of America’s NervGen Pharma NGEN Stock Holding History

Bank of America’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$384K Sell
186,200
-14,456
-7% -$44.9K ﹤0.01% 5093
2026
Q1 		$756K Buy
+200,656
New +$869K ﹤0.01% 4667

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Bank of America's NGEN Position: Q2 2026 in Review

Bank of America reduced its NervGen Pharma (NGEN) stake by 7.2% in Q2 2026, selling an estimated $44.9K and leaving 186,200 shares worth $384K. The position accounts for ﹤0.01% of the portfolio, ranked #5093.

Bank of America first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $756K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Bank of America held 186,200 shares of NervGen Pharma worth $384K as of Q2 2026.
  • Bank of America sold 14,456 NervGen Pharma shares in Q2 2026, an estimated $44.9K.
  • NervGen Pharma made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5093 holding.
  • Bank of America first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • Bank of America's NervGen Pharma position peaked at $756K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.